Published on 24/12/2025
Integrating Epidemiological Data into Geographic Site Planning for Clinical Trials
Introduction: Why Epidemiology Matters in Geographic Planning
Geographic planning for site selection is no longer driven by logistical convenience or investigator relationships alone. Sponsors today rely on robust epidemiological data—such as disease prevalence, incidence, and regional burden—to identify high-opportunity locations for clinical trials. By aligning site geography with epidemiological trends, feasibility teams can optimize patient access, accelerate recruitment, and improve the statistical power and diversity of clinical data.
This article outlines the methodology for incorporating epidemiological data into site selection strategy, identifies key data sources, and offers real-world examples of successful applications in global trials.
1. Understanding Core Epidemiological Concepts
Clinical feasibility teams use three primary epidemiological metrics:
- Prevalence: Total number of existing cases in a population at a given time
- Incidence: Number of new cases occurring in a defined time period
- Burden of Disease: Measured using Disability Adjusted Life Years (DALYs) or Quality Adjusted Life Years (QALYs)
Each of these metrics informs a different aspect of feasibility planning. For example, high prevalence regions are optimal for chronic disease trials, while incidence data is crucial for early detection or screening-based studies.
2. Aligning Disease Distribution with Study Geography
For recruitment success, trials
Example: A sponsor planning a tuberculosis vaccine trial used WHO regional TB incidence maps and prioritized site selection in India, South Africa, and the Philippines—avoiding low-incidence regions like Western Europe, where recruitment was projected to be unviable.
3. Sources of Epidemiological Data for Site Selection
Reliable epidemiological inputs can be sourced from:
- ClinicalTrials.gov: Historical trial location trends and recruitment timelines
- WHO Global Health Observatory: Disease prevalence and incidence by country
- CDC and ECDC: Region-specific surveillance data
- National registries (e.g., India’s CTRI)
- Hospital EHR or claims databases (Real-World Data)
Integration of these data sources into feasibility dashboards enables site teams to visualize recruitment potential geographically.
4. Mapping Disease Burden to Target Regions
Trial feasibility teams often use geospatial disease maps to guide site prioritization. Consider this comparative heatmap example for a global asthma study:
| Country | Asthma Prevalence (%) | Estimated Patient Pool |
|---|---|---|
| Australia | 11.2% | 2.8 million |
| India | 4.3% | 60+ million |
| UK | 8.4% | 5.6 million |
While prevalence may be lower in India, the sheer population size yields a significantly larger patient pool—making it attractive for large-scale recruitment despite infrastructural challenges.
5. Regional Trial Saturation vs. Disease Opportunity
Feasibility should also consider regional saturation. Some countries may have favorable epidemiological profiles but high competition for the same patient group due to overlapping trials.
Solution: Combine prevalence/incidence data with clinical trial density metrics to optimize site placement. This can be done using tools such as:
- ISRCTN Registry: View trial volumes by condition
- ANZCTR: Explore disease-specific trial concentration by region
6. Application in Rare Disease Feasibility
For rare or orphan diseases, epidemiological data is critical to site selection. Identifying national centers of excellence, regional referral patterns, and real-world prevalence data from patient registries is essential for determining where eligible patients are concentrated.
Example: A sponsor designing a rare lysosomal storage disorder trial used registry data from Japan and Canada, identifying five hospitals accounting for 72% of known diagnosed patients globally.
7. Use of DALYs and QALYs in Study Planning
Beyond prevalence and incidence, disease burden (measured by DALYs or QALYs) guides selection for public health studies or value-based endpoints:
- Trials targeting high-DALY conditions may attract government co-funding or fast-track approval
- QALY-based prioritization supports pharmacoeconomic evaluations during post-approval phases
Data source: The Global Burden of Disease Study (IHME database) offers disease burden estimates for over 200 countries.
8. Feasibility Scorecards Using Epidemiology Data
Feasibility teams can create weighted scoring models using epidemiological parameters. Below is a simplified scorecard structure:
| Criteria | Weight | Score (1-5) | Weighted Total |
|---|---|---|---|
| Prevalence (per 100k) | 25% | 4 | 1.0 |
| Incidence Trend (5-year) | 20% | 3 | 0.6 |
| Trial Saturation (inverse) | 20% | 5 | 1.0 |
| Patient Registry Availability | 15% | 4 | 0.6 |
| Regional PI Expertise | 20% | 3 | 0.6 |
| Total Score | 3.8 |
Scores above 3.5 may qualify a region for inclusion in the site list. Anything under 2.5 would be deprioritized.
Conclusion
Epidemiological data is no longer optional in geographic planning—it is foundational. Whether targeting common diseases, rare disorders, or vaccine studies, aligning site selection with where patients live, seek care, and experience the disease in real-world contexts ensures both scientific and operational success. Sponsors should embed structured epidemiological analysis into their feasibility SOPs and cross-reference it with competitive intelligence and logistical constraints to identify truly optimal trial geographies.